RxDoctor Payments Data

Mark Skory, DO

Family Medicine · Auburn, MINPI 1417038449

Payments from drug & device makers

$430in general payments, 2019–2025

Across 28 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$95
  • Lilly USA, LLC$84
  • Johnson & Johnson$61
  • Takeda Pharmaceuticals U.S.A., Inc.$49
  • Pfizer$40
  • Kowa Pharmaceuticals America, Inc.$27
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$41596%
  • Education$154%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$430 in reported general payments places this provider in the 55th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$47,016
Medicare patients
174
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide68$104,759
EliquisApixaban78$86,026
OzempicSemaglutide56$73,201
OtezlaApremilast13$55,418
MounjaroTirzepatide37$54,961
XareltoRivaroxaban45$52,905
RybelsusSemaglutide32$49,244
FarxigaDapagliflozin Propanediol50$48,358
JanuviaSitagliptin Phosphate25$25,586
JardianceEmpagliflozin20$23,730
LinzessLinaclotide24$14,909
Spiriva HandihalerTiotropium Bromide11$12,810
Lantus SolostarInsulin Glargine,hum.Rec.Anlog78$11,432
Atorvastatin Calcium474$6,358
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$5,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$84$159,720105 claims
Novo NordiskOzempic, Rybelsus$95$122,44588 claims
PfizerEliquis$40$86,02678 claims
Johnson & JohnsonXarelto$61$52,90545 claims
AbbVieLinzess$18$14,90924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Auburn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →